Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease

NCT03109353 | Completed Phase 1 DMC

• 1 other identifier: 2016-000872-78
• Study Type: interventional
• Target: 7
• Locations: 1 country
• Sites: 1

Brief Summary

Extracorporeal photopheresis (ECP), is commonly used for the treatment of cutaneous T-cell lymphoma (CTCL) and chronic graft-versus-host disease. ECP (cGVHD) is an immune modulating treatment. White blood cells from the patient are standardized activated by a photosensitizer psoralen (8-MOP) and irradiated with visible ultraviolet light (UV-A). The purpose is to induce programmed cell death (apoptosis). Disadvantage of current treatment is that 8-MOP targets both diseased and normal cells with no selectivity. The purpose of this study is to improve the current ECP technology using aminolevulinic acid (ALA) and UV light. ECP will be carried out in conventional manner except that 8-MOP will be replaced with ALA. Systemic ALA / UV light is already approved and used in the detection and treatment of disease in humans. The primary objective is to assess its safety and tolerability after single and multiple treatment in patients with CTCL or cGvHD.

Conditions

Cutaneous T-Cell Lymphoma, Unspecified; Chronic Graft Versus Host Disease in Skin

Keywords

Photopheresis; 5-aminolevulinic acid; Extracorporeal Circulation

Outcome Measures

Primary Outcomes (1)

• Treatment safety: Monitored through recordings of ECG, vital signs and safety laboratory measurements including haematology, clinical chemistry and urinalysis.

  Monitored through recordings of ECG, vital signs and safety laboratory measurements including haematology, clinical chemistry and urinalysis.

  up to 1 year

Secondary Outcomes (2)

• Main efficacy for CTCL

  up to 1 year

• Main efficacy for cGvHD

  up to 1 year

Study Arms (1)

ALA-ECP

EXPERIMENTAL

Extracorporeal photopheresis (ECP) with 5-aminolevulinic acid replacing psoralen

Drug: ECP with 5-aminolevulinic acid

Interventions

ECP with 5-aminolevulinic acid DRUG

extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles

Also known as: 5-ALA

ALA-ECP

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Informed consent
• cutaneous T-cell lymphoma (CTCL) (Mycosis fungoides and Sézary syndrome)
• considered to respond inadequately to 8-MOP-ECP therapy. Inadequate response is defined as:
• progressive disease: disease progression from baseline in skin score, blood or lymph nodes after 3-6 months or
• stable disease: No- response after 3-6 months or
• minimal response \< 50% (from baseline) reduction of skin scores and/or CD4/CD8 ratio or a loss of peripheral blood clone after 3-6 months.
• (or) chronic graft-versus-host disease (cGvHD) and considered to respond inadequately to 8-MOP-ECP therapy. Chronic GvHD is defined as
• presence of at least 1 clinical sign of cGvHD or
• at least one distinct manifestation confirmed by pertinent biopsy or other relevant tests.
• steroid dependence, intolerance or steroid refractoriness considered to respond inadequately to 8-MOP-ECP therapy with at least monthly intervals.
• Inadequate response is defined as:
• progression of cutaneous cGvHD defined as \>25% worsening from baseline as measured by the percent change in the total skin score or
• after 3 months had an inadequate response of cutaneous cGvHD as defined by \<15% improvement in the total skin score compared with baseline, or a ≤25% reduction in corticosteroid dose.

You may not qualify if:

• Photosensitive comorbidities, porphyria or known hypersensitivity to 5-aminolevulinic acid or porphyrins
• Aphakia
• Pregnancy or breast feeding. (A negative urine pregnancy test must be demonstrated in female patients of child-bearing potential at the Screening Visit)
• Ongoing cardiac and pulmonary diseases or ASAT, ALAT, Bilirubin or INR value ≥ 3x upper limit of normal or clinically significant ECG findings
• Polyneuropathy
• Uncontrolled infection or fever
• History of heparin-induced thrombocytopenia, absolute neutrophil count \<1x10-9 L-, platelet count \<20x10-9 L-1
• Body weight below 40 kg
• Investigator considers subject unlikely to comply with study procedures, restrictions and requirements.
• History of any clinically significant disease or disorder which in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the result or the patient's ability to participate in the study.

Sponsors & Collaborators

• St. Olavs Hospital: lead
• Norwegian University of Science and Technology: collaborator
• Oslo University Hospital: collaborator

Study Sites (1)

St Olavs Hospital

Trondheim, Norway

Location

MeSH Terms

Conditions

Lymphoma, T-Cell, Cutaneous

Interventions

Eosinophil Cationic Protein; Aminolevulinic Acid

Condition Hierarchy (Ancestors)

Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Endoribonucleases; Ribonucleases; Esterases; Hydrolases; Enzymes; Enzymes and Coenzymes; Eosinophil Granule Proteins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Levulinic Acids; Keto Acids; Carboxylic Acids; Organic Chemicals; Amino Acids

Study Officials

• Vigleik Jessen, md

  St Olavs Hospital, Trondheim Unversity Hospital

  STUDY DIRECTOR

• Torstein Baade Rø, md phd

  Norwegian University of Science and Technology

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2017
• First Posted: April 12, 2017
• Study Start: September 20, 2017
• Primary Completion: December 31, 2022
• Study Completion: December 31, 2022
• Last Updated: January 13, 2023

Record last verified: 2023-01

Locations

NO (1)